scholarly journals Urinary Liver-Type Fatty Acid-Binding Protein Level as a Predictive Biomarker of Acute Kidney Injury in Patients with Acute Decompensated Heart Failure

2017 ◽  
Vol 7 (4) ◽  
pp. 267-275 ◽  
Author(s):  
Keiichi Hishikari ◽  
Hiroyuki Hikita ◽  
Shun Nakamura ◽  
Shun Nakagama ◽  
Masahumi Mizusawa ◽  
...  
Keyword(s):  
Heart Failure ◽  
Acute Kidney Injury ◽  
Fatty Acid ◽  
Fatty Acid Binding Protein ◽  
Acute Decompensated Heart Failure ◽  
Binding Protein ◽  
Kidney Injury ◽  
Decompensated Heart Failure ◽  
Fatty Acid Binding ◽  
Acid Binding Protein

Background: There are no biological markers to predict the onset of acute kidney injury (AKI) in patients with acute decompensated heart failure (ADHF). Liver-type fatty acid-binding protein (L-FABP) levels are markedly upregulated in the proximal tubules after renal ischemia. We investigated whether urinary L-FABP is a suitable marker to predict AKI in ADHF patients. Methods: We examined 281 consecutive patients with ADHF. Serum creatinine (Cr) and L-FABP levels were measured at admission and 24 and 48 h after admission. Results: AKI developed in 104 patients (37%). Urinary L-FABP levels at admission were significantly higher in patients with AKI than in those without (33.0 vs. 5.2 μg/g Cr; p < 0.001). Multivariate analysis showed that baseline urinary L-FABP level was an independent predictor of AKI in ADHF patients (odds ratio 1.08, 95% confidence interval 1.05-1.12; p < 0.001). Receiver operating characteristic analysis showed that baseline urinary L-FABP level exhibited 94.2% sensitivity and 87.0% specificity at a cutoff value of 12.5 μg/g Cr. Conclusions: Urinary L-FABP level is useful for predicting the onset of AKI in patients with ADHF. The results of our study could help clinicians diagnose AKI in ADHF patients earlier, leading to possible improvements in the treatment of this group of patients.

scholarly journals Circulating intestinal fatty acid-binding protein (I-FABP) levels in acute decompensated heart failure

2017 ◽  
Vol 50 (9) ◽  
pp. 491-495 ◽  
Author(s):  
Takeshi Kitai ◽  
Yong-Hyun Kim ◽  
Kathryn Kiefer ◽  
Rommel Morales ◽  
Allen G. Borowski ◽  
...  
Keyword(s):  
Heart Failure ◽  
Fatty Acid ◽  
Fatty Acid Binding Protein ◽  
Acute Decompensated Heart Failure ◽  
Binding Protein ◽  
Decompensated Heart Failure ◽  
Fatty Acid Binding ◽  
Acid Binding Protein

Heart-Type Fatty Acid Binding Protein (H-FABP) in Acute Decompensated Heart Failure

2010 ◽  
Vol 16 (9) ◽  
pp. S166 ◽  
Author(s):  
Mitsunori Ishino ◽  
Tetsuro Shishido ◽  
Takanori Arimoto ◽  
Hiroki Takahashi ◽  
Takehiko Miyashita ◽  
...  
Keyword(s):  
Heart Failure ◽  
Fatty Acid ◽  
Fatty Acid Binding Protein ◽  
Acute Decompensated Heart Failure ◽  
Binding Protein ◽  
Decompensated Heart Failure ◽  
Fatty Acid Binding ◽  
Acid Binding Protein

scholarly journals Performance of Urinary Liver-Type Fatty Acid–Binding Protein in Acute Kidney Injury: A Meta-analysis

2013 ◽  
Vol 61 (3) ◽  
pp. 430-439 ◽  
Author(s):  
Paweena Susantitaphong ◽  
Monchai Siribamrungwong ◽  
Kent Doi ◽  
Eisei Noiri ◽  
Norma Terrin ◽  
...  
Keyword(s):  
Acute Kidney Injury ◽  
Fatty Acid ◽  
Fatty Acid Binding Protein ◽  
Binding Protein ◽  
Meta Analysis ◽  
Kidney Injury ◽  
Fatty Acid Binding ◽  
Acid Binding Protein

scholarly journals Clinical Usefulness of Urinary Liver Fatty Acid-Binding Protein Excretion for Predicting Acute Kidney Injury during the First 7 Days and the Short-Term Prognosis in Acute Heart Failure Patients with Non-Chronic Kidney Disease

2017 ◽  
Vol 7 (4) ◽  
pp. 301-315 ◽  
Author(s):  
Akihiro Shirakabe ◽  
Noritake Hata ◽  
Nobuaki Kobayashi ◽  
Hirotake Okazaki ◽  
Masato Matsushita ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Kidney Disease ◽  
Acute Kidney Injury ◽  
Fatty Acid ◽  
Kidney Disease ◽  
Fatty Acid Binding Protein ◽  
Kidney Injury ◽  
Liver Fatty Acid ◽  
Fatty Acid Binding ◽  
Acid Binding Protein

Background: The clinical significance of urinary liver fatty acid-binding protein (u-LFABP) in acute heart failure (AHF) patients remains unclear. Methods and Results: The u-LFABP levels on admission of 293 AHF patients were analyzed. The patients were divided into 2 groups according to the u-LFABP quartiles (Q1, Q2, and Q3 = low u-LFABP [L] group vs. Q4 = high u-LFABP [H] group). We evaluated the diagnostic and prognostic value of u-LFABP and compared the findings between the chronic kidney disease (CKD; n = 165) and non-CKD patients (n = 128). Acute kidney injury (AKI) during the first 7 days was evaluated based on the RIFLE criteria. In the non-CKD group, the number of AKI patients during the first 7 days was significantly greater in the H group (70.0%) than in the L group (45.6%). A multivariate logistic regression model indicated that the H group (odds ratio: 3.850, 95% confidence interval [CI] 1.128-13.140) was independently associated with AKI during the first 7 days. The sensitivity and specificity of u-LFABP for predicting AKI were 63.6 and 59.7% (area under the ROC curve 0.631) at 41.9 ng/mg × cre. A Cox regression model identified the H group (hazard ratio: 13.494, 95% CI 1.512-120.415) as an independent predictor of the 60-day mortality. A Kaplan-Meier curve, including all-cause death within 60 days, showed a significantly poorer survival rate in the H group than in the L group (p = 0.036). Conclusions: The u-LFABP level is an effective biomarker for predicting AKI during the first 7 days of hospitalization and an adverse outcome in AHF patients with non-CKD.

Sign in / Sign up

Export Citation Format

Share Document